Loading...

Biosearch

BST:PUL
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PUL
BST
€87M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors in Spain and internationally. The last earnings update was 79 days ago. More info.


Add to Portfolio Compare Print Invest
PUL Share Price and Events
Price Volatility
PUL
Industry
5yr Volatility vs Market

Value

 Is Biosearch undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biosearch to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biosearch.

BST:PUL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:PUL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.76
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.757 (1 + (1- 25%) (5.2%))
0.787
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.8 * 9.46%)
8.11%

Discounted Cash Flow Calculation for BST:PUL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biosearch is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:PUL DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 0.56 0.62 0.69 0.77 0.85
Source Est @ 10.86% Est @ 10.86% Est @ 10.86% Est @ 10.86% Est @ 10.86%
Present Value
Discounted (@ 8.11%)
0.52 0.53 0.55 0.56 0.58
Present value of next 5 years cash flows €2.74
BST:PUL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €0.85 × (1 + 0.54%) ÷ (8.11% – 0.54%)
€11.31
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €11.31 ÷ (1 + 8.11%)5
€7.66
BST:PUL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €2.74 + €7.66
€10.40
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €10.40 / 57.69
€0.2
BST:PUL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:PUL represents 1.11525x of BME:BIO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.11525x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 0.18 x 1.11525
€0.20
Value per share (EUR) From above. €0.20
Current discount Discount to share price of €1.65
= -1 x (€1.65 - €0.20) / €0.20
-718.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Biosearch is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biosearch's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biosearch's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:PUL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €0.04
BME:BIO Share Price ** BME (2018-07-17) in EUR €1.48
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 31.17x
Germany Market PE Ratio Median Figure of 407 Publicly-Listed Companies 18.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biosearch.

BST:PUL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:BIO Share Price ÷ EPS (both in EUR)

= 1.48 ÷ 0.04

36.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biosearch is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Biosearch is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Biosearch's expected growth come at a high price?
Raw Data
BST:PUL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 36.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.61x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biosearch, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biosearch's assets?
Raw Data
BST:PUL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.36
BME:BIO Share Price * BME (2018-07-17) in EUR €1.48
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.43x
Germany Market PB Ratio Median Figure of 547 Publicly-Listed Companies 1.86x
BST:PUL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:BIO Share Price ÷ Book Value per Share (both in EUR)

= 1.48 ÷ 0.36

4.12x

* Primary Listing of Biosearch.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biosearch is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Biosearch's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biosearch has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Biosearch expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosearch has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.8%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biosearch expected to grow at an attractive rate?
  • Unable to compare Biosearch's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Biosearch's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Biosearch's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:PUL Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 50.8%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:PUL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:PUL Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 28 3 3
2018-03-31 26 3 3
2017-12-31 25 2 2
2017-09-30 24 3 -0
2017-06-30 23 3 -3
2017-03-31 23 3 -3
2016-12-31 23 3 -3
2016-09-30 22 2 -2
2016-06-30 21 1 -0
2016-03-31 20 1 -0
2015-12-31 19 2 -0
2015-09-30 19 -0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Biosearch is high growth as no earnings estimate data is available.
  • Unable to determine if Biosearch is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:PUL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Biosearch Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:PUL Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30
2018-03-31
2017-12-31 0.04
2017-09-30 -0.01
2017-06-30
2017-03-31
2016-12-31 -0.06
2016-09-30 -0.03
2016-06-30
2016-03-31
2015-12-31 -0.01
2015-09-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biosearch will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Biosearch's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Biosearch's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Biosearch's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Biosearch's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biosearch has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Biosearch performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biosearch's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biosearch's year on year earnings growth rate has been positive over the past 5 years.
  • Biosearch has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Biosearch has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Biosearch's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biosearch Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:PUL Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 27.57 3.14 7.04
2018-03-31 26.43 2.59 6.85
2017-12-31 25.28 2.04 6.65
2017-09-30 24.28 -0.44 6.41
2017-06-30 23.28 -2.92 6.17
2017-03-31 23.06 -3.13 6.19
2016-12-31 22.85 -3.33 6.21
2016-09-30 21.95 -1.71 6.09
2016-06-30 21.05 -0.09 5.96
2016-03-31 20.13 -0.21 5.68
2015-12-31 19.21 -0.32 5.40
2015-09-30 18.67 -0.45 5.24
2015-06-30 18.14 -0.59 5.08
2015-03-31 17.78 -0.59 5.00
2014-12-31 17.43 -0.60 4.92
2014-09-30 17.04 -0.47 4.95
2014-06-30 16.66 -0.35 4.97
2014-03-31 16.95 -0.21 4.86
2013-12-31 17.25 -0.07 4.74
2013-09-30 16.78 -0.29 4.65
2013-06-30 16.32 -0.51 4.56
2013-03-31 16.31 -0.72 4.63
2012-12-31 16.29 -0.92 4.69
2012-09-30 16.51 -2.44 4.71
2012-06-30 16.73 -3.97 4.74
2012-03-31 16.01 -4.03 4.73
2011-12-31 15.29 -4.10 4.72

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Biosearch has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Biosearch used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Biosearch has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Biosearch's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biosearch has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Biosearch's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biosearch's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biosearch is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biosearch's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biosearch's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biosearch Company Filings, last reported 3 months ago.

BST:PUL Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 22.13 4.52 0.67
2018-03-31 22.13 4.52 0.67
2017-12-31 20.65 5.61 0.69
2017-09-30 20.65 5.61 0.69
2017-06-30 19.10 6.36 0.11
2017-03-31 19.10 6.36 0.11
2016-12-31 18.80 7.34 0.26
2016-09-30 18.80 7.34 0.26
2016-06-30 22.38 9.72 0.01
2016-03-31 22.38 9.72 0.01
2015-12-31 22.39 10.01 0.13
2015-09-30 22.39 10.01 0.13
2015-06-30 22.33 9.85 0.04
2015-03-31 22.33 9.85 0.04
2014-12-31 22.70 10.60 0.22
2014-09-30 22.70 10.60 0.22
2014-06-30 23.04 11.96 0.20
2014-03-31 23.04 11.96 0.20
2013-12-31 23.43 12.77 0.40
2013-09-30 23.43 12.77 0.40
2013-06-30 23.45 14.10 0.44
2013-03-31 23.45 14.10 0.44
2012-12-31 23.61 14.62 0.22
2012-09-30 23.61 14.62 0.22
2012-06-30 24.39 14.62 0.36
2012-03-31 24.39 14.62 0.36
2011-12-31 25.01 14.96 1.27
  • Biosearch's level of debt (20.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (60.1% vs 20.4% today).
  • Debt is well covered by operating cash flow (62.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 44.6x coverage).
X
Financial health checks
We assess Biosearch's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biosearch has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Biosearch's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biosearch dividends.
If you bought €2,000 of Biosearch shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biosearch's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biosearch's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:PUL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biosearch has not reported any payouts.
  • Unable to verify if Biosearch's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biosearch's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biosearch has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biosearch's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biosearch afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biosearch has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Biosearch's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
José María   Roset Monrós , image provided by Google.
José María Roset Monrós
CEO Bio

Mr. José María Roset Monros serves as the Chief Executive Officer of Biosearch SA (alternate name: Puleva Biotech SA) and served as its General Director. Mr. Monros served as the Chief Financial Officer of Puleva Biotech SA.

CEO Compensation
  • Insufficient data for José María to compare compensation growth.
  • Insufficient data for José María to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

José María Roset Monrós

TITLE
Chief Executive Officer

Loreto Huertas De La Cámara

TITLE
Chief Financial Officer

Alejandro Jara García Navas

TITLE
Operations Director

Monica Olivares Martin

TITLE
Research Director

Santiago De La Escalera

TITLE
Development Director

Emma Madrid Sanchez-Gómez

TITLE
Human Resources Director

David López Medina

TITLE
Secretary of the Board of Directors
TENURE
7.8 yrs

Ana María Moreno Jimenez

TITLE
Food Safety & Quality Director

Antonio Martinez Descalzo

TITLE
Commercial Director

Jaime Lancha Fernández

TITLE
Logistics & Purchases Director
Board of Directors Tenure

Average tenure of the Biosearch board of directors in years:

6.3
Average Tenure
  • The tenure for the Biosearch board of directors is about average.
Board of Directors

José Antonio Lalanda Sanmiguel

TITLE
Chairman
COMPENSATION
€3K
TENURE
4.3 yrs

José María De León Molinari

TITLE
Independent Director
COMPENSATION
€36K
TENURE
14.3 yrs

Laureano Roldán Aguilar

TITLE
Non-Executive Independent Director
COMPENSATION
€33K
AGE
56
TENURE
16 yrs

Pedro Gómez de Baeza Tinture

TITLE
Non-Executive Independent Director
COMPENSATION
€34K
TENURE
14.4 yrs

José Cerezuela Rodríguez

TITLE
Proprietary Member of the Board of Directors
COMPENSATION
€5K
TENURE
6.3 yrs

Erick Boutry

TITLE
Proprietary Member of the Board of Directors
COMPENSATION
€1,000
TENURE
7.8 yrs

Christophe Latron

TITLE
Proprietary Member of the Board of Directors
COMPENSATION
€1,000
TENURE
6.3 yrs

Isidoro de la Escalera Álvarez

TITLE
Independent Director
COMPENSATION
€34K
AGE
53
TENURE
6.3 yrs

Javier Santiso Guimaras

TITLE
Independent Director
COMPENSATION
€1,000
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
29. Dec 17 Buy Isidoro de la Escalera Álvarez Individual 28. Dec 17 28. Dec 17 35,000 $25,510.80
05. Dec 17 Buy Aurelio Antuña Rodriguez Individual 22. Nov 17 22. Nov 17 17,578 $10,158.29
X
Management checks
We assess Biosearch's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biosearch has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors in Spain and internationally. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.

Details
Name: Biosearch, S.A.
PUL
Exchange: BST
Founded:
€86,829,509
57,694,026
Website: http://www.biosearchlife.com
Address: Biosearch, S.A.
Camino de Purchil, 66,
Granada,
18004,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME BIO Common Stock Bolsas y Mercados Espanoles ES EUR 17. Dec 2001
DB PUL Common Stock Deutsche Boerse AG DE EUR 17. Dec 2001
BST PUL Common Stock Boerse-Stuttgart DE EUR 17. Dec 2001
LSE 0MZV Common Stock London Stock Exchange GB EUR 17. Dec 2001
BATS-CHIXE BIOE Common Stock BATS 'Chi-X Europe' GB EUR 17. Dec 2001
Number of employees
Current staff
Staff numbers
152
Biosearch employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/14 18:22
End of day share price update: 2018/07/17 00:00
Last earnings filing: 2018/07/27
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.